Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_4
1
33%
Ph phase_2
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Completed1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

completed133%
recruiting133%
active_not_recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
completedphase_4

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

NCT03190330
active_not_recruitingphase_1

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

NCT03379428
recruitingphase_2

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

NCT05694312

Clinical Trials (3)

Showing 3 of 3 trials
NCT03190330Phase 4

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Completed
NCT03379428Phase 1

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Active Not Recruiting
NCT05694312Phase 2

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3